This review highlights KRAS G12C challenges and summarizes clinical evidence in colorectal cancer and lung cancer, indicating future research directions.
Key Points
KRAS G12C mutation is present in about 3–4% of colorectal cancers and 12–14% of non-small cell lung cancers, contributing to aggressive tumor behavior.
Targeting the KRAS G12C mutation with covalent inhibitors like sotorasib and adagrasib demonstrates clinical activity in previously treated colorectal cancer and non-small cell lung cancer.
Despite advancements, significant challenges remain, including primary and acquired resistance to therapy and toxicity management in patients.
Developing strategies to optimize doses and navigate resistance is crucial for enhancing treatment outcomes in KRAS G12C-mutant cancers.